8 news items
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
President, Vaccines Innovation Unit, CSL.
"We are thrilled that the results of the ARCT-154 study have been
Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine
ARCT
CSLLY
20 May 24
Jon Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
ARCT
15 May 24
for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
ARCT
8 May 24
to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
ARCT
25 Apr 24
has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture
xklj60rfjgonmaid3bahntfmxzbu0ykbp3a0sgeql0 1fnfen85hg1t6
ARCT
7 Mar 24
an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture
8v8m78kpoguodqi6q 3wkxj4e9p33qdndsz42yewqscog2
ARCT
26 Feb 24
RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus
tfii1knp445bu4q28s
ARCT
22 Feb 24
RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus
- Prev
- 1
- Next